Abstract
The effect of apomorphine or of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO 20–1724), a potent phosphodiesterase inhibitor, on levels of cyclic AMP and cyclic GMP in vivo was examined in the pituitary, cerebellum, corpus striatum and nucleus accumbens-olfactory tubercle. RO 20–1724 was also tested in combination with apomorphine to determine whether this drug could potentiate the effect of apomorphine. Rats were injected with vehicle or RO 20–1724 (30 mg/kg) 30 min prior to an injection of saline or apomorphine hydrochloride (1 or 10 mg/kg). The animals were killed by microwave irradiation 7 min after the second injection. RO 20–1724 increased levels of cyclic AMP in all four regions, especially in the pituitary. RO 20–1724 increased levels of cyclic GMP in the cerebellum, but not in the pituitary. Apomorphine increased cyclic AMP in the pituitary, and cyclic GMP in all four regions. RO 20-1724 did not produce supra-additive effects with apomorphine. The system most responsive to either drug was cyclic AMP in the pituitary, where cyclic AMP increased approximately 10-fold after either apomorphine or RO 20–1724.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
